Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway

Fig. 4

Improved CDX2 restoration in COLO205 cells upon combining DNMTi and HDACi treatment. a qPCR analysis of COLO205 cells treated for 48 h with DNMTi decitabine (2.5 μM, 5 μM, 10 μM) alone and in combination with the general HDACi trichostatin A (TSA; 50 nM) or the specific HDAC4/5 inhibitor LMK-235 (20 nM). Analysis as in Fig. 5a. MWU: ***p < 0.001, (n = 4). b CDX2 Western blot analysis of COLO205 cells treated as in a. Total protein is shown as a loading control. c Immunohistochemistry (IHC) analysis of COLO205 cells treated with decitabine (5 μM), TSA (50 nM), or LMK-235 (20 nM) alone or combination treatments with decitabine and TSA or LMK-235

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us